EU countries unprepared to move Alzheimer’s treatment into clinical use, study indicates

Written by Sharon Salt, Editor

According to a new Rand Corporation (CA, USA) study, the healthcare systems in some European countries lack the capacity to rapidly move a disease-modifying treatment for Alzheimer’s disease approval into widespread clinical use. The researchers analyzed the preparedness of the healthcare systems in six European countries – France, Germany, Italy, Spain, Sweden and the UK – to ensure timely diagnosis and treatment of patients if a disease-modifying therapy for Alzheimer’s becomes available. In the study, it was determined that the primary problem is the need for medical specialists trained to diagnose people who may have early signs of Alzheimer’s and...

To view the full article, please register now for access

It's completely free